What question did this study set out to answer?

This study aims to determine the incidence of BK virus nephropathy among kidney transplant recipients and its associated factors.

January 14, 2026Open Access

P-1806. Incidence of BK Virus Nephropathy in Kidney Transplant Recipients

Key Points

This study aims to determine the incidence of BK virus nephropathy among kidney transplant recipients and its associated factors.
Prospective cohort study of kidney transplant recipients with BKV reactivation confirmed by quantitative PCR.
Chi-square tests for categorical variables and Student’s t-test for mean differences were utilized.
Clinical data on immunosuppression, rejection, and BKVAN were collected.
33.7% of kidney transplant recipients had BK virus reactivation in urine, with 13.4% in plasma.
23.5% of recipients with BK virus reactivation developed BK virus nephropathy (BKVAN).
81.3% of BKVAN patients experienced rejection, with a median time to diagnosis of 143 days.

Abstract

Abstract Background BK virus (BKV) reactivation in urine and plasma occurs in 30–60% and 4.5–27% of kidney transplant (KT) recipients, respectively. Of these, 1–5% will develop BKV-associated nephropathy (BKVAN), which can lead to graft loss. BKVAN is defined as histological changes in the graft secondary to BKV reactivation. Methods This was a prospective cohort study. KT recipients with BKV reactivation in urine and plasma confirmed by quantitative PCR at a University Hospital (January 2020 – December 2024) were included. Chi-square tests were used for categorical variables and Student’s t-test for differences in means and medians; interquartile range (IQR) was reported for continuous variables. Results During the study period, 202 KTs were performed, of which 68 (33.7%) had BKV reactivation in urine, and 27 (13.4%) also in plasma. BKV reactivation occurred more than once in 34.1% of cases. Sixteen recipients (23.5%) developed BKVAN. Of these, 81.3% were male. The median age was 53.9 years (IQR 50.5–57.2). Donor type was deceased (75%), unrelated living (5.9%), and related living (19.1%). Induction immunosuppression included corticosteroids (100%), thymoglobulin (86%), mycophenolate (82.8%), tacrolimus (10.9%), and rituximab (4.7%). 6.8% of KT receptors had concurrent CMV infection. Among BKVAN patients, 81.3% experienced rejection and 14.3% lost the graft. The median time from transplant to BKVAN diagnosis was 143 days (IQR 83–853). Recent organ rejection was the only factor associated with BKVAN (p 0.0001). Clinical presentation included renal insufficiency (56.8%), dysuria (15.9%), hematuria (4.5%), and fever (2.3%). Treatment involved reduction of immunosuppression (77%), regimen changes (40.9%), and leflunomide administration (37%). No hospitalizations or BKVAN-related deaths were recorded. Conclusion The incidence of BKVAN was higher than that reported in the literature. Rejection was the only factor associated with BKVAN, suggesting its role in disease progression. Disclosures All Authors: No reported disclosures

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Ramponi et al. (Thu,) studied this question.

synapsesocial.com/papers/6966e70e13bf7a6f02bff358 https://doi.org/https://doi.org/10.1093/ofid/ofaf695.1975

Demander à l'IA

Bookmark

View Full Paper